Clinical differences among patients with myeloperoxidase-antineutrophil cytoplasmic antibody-positive interstitial lung disease. 2023

Koichi Yamaguchi, and Aya Yamaguchi, and Masashi Ito, and Ikuo Wakamatsu, and Miki Itai, and Sohei Muto, and Shogo Uno, and Masaki Aikawa, and Shunichi Kouno, and Masao Takemura, and Masakiyo Yatomi, and Haruka Aoki-Saito, and Yasuhiko Koga, and Kenichiro Hara, and Shinsuke Motegi, and Mayuko Tsukida, and Fumie Ota, and Yoshito Tsukada, and Mitsuru Motegi, and Masao Nakasatomi, and Toru Sakairi, and Hidekazu Ikeuchi, and Yoriaki Kaneko, and Keiju Hiromura, and Toshitaka Maeno
Department of Allergy and Respiratory Medicine, Gunma University Graduate School of Medicine, 3-39-15 Showa-machi, Gunma, 371-8511, Japan. ckpnt341@yahoo.co.jp.

BACKGROUND Patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis and idiopathic interstitial lung diseases (IIPs) are positive for myeloperoxidase (MPO)-ANCA. MPO-ANCA-positive vasculitis mainly comprises microscopic polyangiitis (MPA) and unclassifiable vasculitis. These diseases are frequently complicated by interstitial lung disease (ILD). Few studies have reported the clinical differences between the subtypes of MPO-ANCA-positive ILD. Therefore, this study aimed to examine the clinical findings and courses of MPO-ANCA-positive ILD. METHODS This retrospective study enrolled 100 patients with MPO-ANCA-positive ILD who were categorized into three groups: MPA (n = 44), unclassifiable vasculitis (n = 29), and IIP (n = 27). Our study compared the clinical findings and prognosis of these patients and analyzed the poor prognostic factors. Furthermore, we assessed the association between the patients with and without acute exacerbation of ILD (AE-ILD). RESULTS Our study found clinical differences in serum markers, clinical symptoms, and treatment regimens among the three groups. ILD complications, as the main cause of death, differed among the three groups (P = 0.04). Patients with unclassifiable vasculitis showed higher survival rates than those with IIP (P = 0.046). Patients with AE-ILD showed fewer general symptoms (P = 0.02) and lower survival rates (P < 0.01) than those without AE-ILD. In multivariate analysis, AE-ILD development was a strong poor prognostic factor for MPO-ANCA-positive ILD. CONCLUSIONS The subtypes of MPO-ANCA-positive ILD have different clinical features and prognoses. Patients who develop AE-ILD require careful evaluation of clinical courses. Key Points • In myeloperoxidase (MPO)-antineutrophil cytoplasmic antibody (ANCA)-positive interstitial lung disease (ILD), patients with unclassifiable vasculitis showed a better prognosis than those with idiopathic ILD.. • Development of acute exacerbation in ILD was a strong poor prognostic factor in patients with MPO-ANCA-positive ILD..

UI MeSH Term Description Entries
D009195 Peroxidase A hemeprotein from leukocytes. Deficiency of this enzyme leads to a hereditary disorder coupled with disseminated moniliasis. It catalyzes the conversion of a donor and peroxide to an oxidized donor and water. EC 1.11.1.7. Myeloperoxidase,Hemi-Myeloperoxidase,Hemi Myeloperoxidase
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D012189 Retrospective Studies Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons. Retrospective Study,Studies, Retrospective,Study, Retrospective
D017563 Lung Diseases, Interstitial A diverse group of lung diseases that affect the lung parenchyma. They are characterized by an initial inflammation of PULMONARY ALVEOLI that extends to the interstitium and beyond leading to diffuse PULMONARY FIBROSIS. Interstitial lung diseases are classified by their etiology (known or unknown causes), and radiological-pathological features. Diffuse Parenchymal Lung Disease,Diffuse Parenchymal Lung Diseases,Interstitial Lung Disease,Interstitial Lung Diseases,Pneumonia, Interstitial,Pneumonitis, Interstitial,Interstitial Pneumonia,Interstitial Pneumonias,Interstitial Pneumonitides,Interstitial Pneumonitis,Lung Disease, Interstitial,Pneumonias, Interstitial,Pneumonitides, Interstitial
D055953 Microscopic Polyangiitis A primary systemic vasculitis of small- and some medium-sized vessels. It is characterized by a tropism for kidneys and lungs, positive association with anti-neutrophil cytoplasmic antibodies (ANCA), and a paucity of immunoglobulin deposits in vessel walls. Microscopic Polyangiitides,Polyangiitides, Microscopic,Polyangiitis, Microscopic
D056648 Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis Group of systemic vasculitis with a strong association with ANCA. The disorders are characterized by necrotizing inflammation of small and medium size vessels, with little or no immune-complex deposits in vessel walls. ANCA-Associated Vasculitides,ANCA-Associated Vasculitis,Pauci-Immune Vasculitis,ANCA Associated Vasculitides,ANCA Associated Vasculitis,ANCA-Associated Vasculitide,Anti Neutrophil Cytoplasmic Antibody Associated Vasculitis,Pauci Immune Vasculitis,Pauci-Immune Vasculitides,Vasculitide, ANCA-Associated,Vasculitides, ANCA-Associated,Vasculitides, Pauci-Immune,Vasculitis, ANCA-Associated,Vasculitis, Pauci-Immune
D019268 Antibodies, Antineutrophil Cytoplasmic Autoantibodies directed against cytoplasmic constituents of POLYMORPHONUCLEAR LEUKOCYTES and/or MONOCYTES. They are used as specific markers for GRANULOMATOSIS WITH POLYANGIITIS and other diseases, though their pathophysiological role is not clear. ANCA are routinely detected by indirect immunofluorescence with three different patterns: c-ANCA (cytoplasmic), p-ANCA (perinuclear), and atypical ANCA. ANCA,Anti-Neutrophil Cytoplasmic Autoantibodies,Anti-Neutrophil Cytoplasmic Autoantibody,Antineutrophil Cytoplasmic Antibodies,Neutrophil Cytoplasmic Autoantibodies,Neutrophil Cytoplasmic Autoantibody,c-ANCA,p-ANCA,Anti-Neutrophil Cytoplasmic Antibodies,Anti-Neutrophil Cytoplasmic Antibody,Antineutrophil Cytoplasmic Antibody,Anti Neutrophil Cytoplasmic Antibodies,Anti Neutrophil Cytoplasmic Antibody,Anti Neutrophil Cytoplasmic Autoantibodies,Anti Neutrophil Cytoplasmic Autoantibody,Antibody, Anti-Neutrophil Cytoplasmic,Antibody, Antineutrophil Cytoplasmic,Autoantibody, Anti-Neutrophil Cytoplasmic,Autoantibody, Neutrophil Cytoplasmic,Cytoplasmic Antibody, Anti-Neutrophil,Cytoplasmic Antibody, Antineutrophil,Cytoplasmic Autoantibody, Anti-Neutrophil,Cytoplasmic Autoantibody, Neutrophil,c ANCA,p ANCA

Related Publications

Koichi Yamaguchi, and Aya Yamaguchi, and Masashi Ito, and Ikuo Wakamatsu, and Miki Itai, and Sohei Muto, and Shogo Uno, and Masaki Aikawa, and Shunichi Kouno, and Masao Takemura, and Masakiyo Yatomi, and Haruka Aoki-Saito, and Yasuhiko Koga, and Kenichiro Hara, and Shinsuke Motegi, and Mayuko Tsukida, and Fumie Ota, and Yoshito Tsukada, and Mitsuru Motegi, and Masao Nakasatomi, and Toru Sakairi, and Hidekazu Ikeuchi, and Yoriaki Kaneko, and Keiju Hiromura, and Toshitaka Maeno
August 2019, Annals of the rheumatic diseases,
Koichi Yamaguchi, and Aya Yamaguchi, and Masashi Ito, and Ikuo Wakamatsu, and Miki Itai, and Sohei Muto, and Shogo Uno, and Masaki Aikawa, and Shunichi Kouno, and Masao Takemura, and Masakiyo Yatomi, and Haruka Aoki-Saito, and Yasuhiko Koga, and Kenichiro Hara, and Shinsuke Motegi, and Mayuko Tsukida, and Fumie Ota, and Yoshito Tsukada, and Mitsuru Motegi, and Masao Nakasatomi, and Toru Sakairi, and Hidekazu Ikeuchi, and Yoriaki Kaneko, and Keiju Hiromura, and Toshitaka Maeno
December 2021, European respiratory review : an official journal of the European Respiratory Society,
Koichi Yamaguchi, and Aya Yamaguchi, and Masashi Ito, and Ikuo Wakamatsu, and Miki Itai, and Sohei Muto, and Shogo Uno, and Masaki Aikawa, and Shunichi Kouno, and Masao Takemura, and Masakiyo Yatomi, and Haruka Aoki-Saito, and Yasuhiko Koga, and Kenichiro Hara, and Shinsuke Motegi, and Mayuko Tsukida, and Fumie Ota, and Yoshito Tsukada, and Mitsuru Motegi, and Masao Nakasatomi, and Toru Sakairi, and Hidekazu Ikeuchi, and Yoriaki Kaneko, and Keiju Hiromura, and Toshitaka Maeno
May 2015, Genetics and molecular research : GMR,
Koichi Yamaguchi, and Aya Yamaguchi, and Masashi Ito, and Ikuo Wakamatsu, and Miki Itai, and Sohei Muto, and Shogo Uno, and Masaki Aikawa, and Shunichi Kouno, and Masao Takemura, and Masakiyo Yatomi, and Haruka Aoki-Saito, and Yasuhiko Koga, and Kenichiro Hara, and Shinsuke Motegi, and Mayuko Tsukida, and Fumie Ota, and Yoshito Tsukada, and Mitsuru Motegi, and Masao Nakasatomi, and Toru Sakairi, and Hidekazu Ikeuchi, and Yoriaki Kaneko, and Keiju Hiromura, and Toshitaka Maeno
October 2023, Scientific reports,
Koichi Yamaguchi, and Aya Yamaguchi, and Masashi Ito, and Ikuo Wakamatsu, and Miki Itai, and Sohei Muto, and Shogo Uno, and Masaki Aikawa, and Shunichi Kouno, and Masao Takemura, and Masakiyo Yatomi, and Haruka Aoki-Saito, and Yasuhiko Koga, and Kenichiro Hara, and Shinsuke Motegi, and Mayuko Tsukida, and Fumie Ota, and Yoshito Tsukada, and Mitsuru Motegi, and Masao Nakasatomi, and Toru Sakairi, and Hidekazu Ikeuchi, and Yoriaki Kaneko, and Keiju Hiromura, and Toshitaka Maeno
January 2019, Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG,
Koichi Yamaguchi, and Aya Yamaguchi, and Masashi Ito, and Ikuo Wakamatsu, and Miki Itai, and Sohei Muto, and Shogo Uno, and Masaki Aikawa, and Shunichi Kouno, and Masao Takemura, and Masakiyo Yatomi, and Haruka Aoki-Saito, and Yasuhiko Koga, and Kenichiro Hara, and Shinsuke Motegi, and Mayuko Tsukida, and Fumie Ota, and Yoshito Tsukada, and Mitsuru Motegi, and Masao Nakasatomi, and Toru Sakairi, and Hidekazu Ikeuchi, and Yoriaki Kaneko, and Keiju Hiromura, and Toshitaka Maeno
July 2010, Japanese journal of ophthalmology,
Koichi Yamaguchi, and Aya Yamaguchi, and Masashi Ito, and Ikuo Wakamatsu, and Miki Itai, and Sohei Muto, and Shogo Uno, and Masaki Aikawa, and Shunichi Kouno, and Masao Takemura, and Masakiyo Yatomi, and Haruka Aoki-Saito, and Yasuhiko Koga, and Kenichiro Hara, and Shinsuke Motegi, and Mayuko Tsukida, and Fumie Ota, and Yoshito Tsukada, and Mitsuru Motegi, and Masao Nakasatomi, and Toru Sakairi, and Hidekazu Ikeuchi, and Yoriaki Kaneko, and Keiju Hiromura, and Toshitaka Maeno
October 1999, Internal medicine (Tokyo, Japan),
Koichi Yamaguchi, and Aya Yamaguchi, and Masashi Ito, and Ikuo Wakamatsu, and Miki Itai, and Sohei Muto, and Shogo Uno, and Masaki Aikawa, and Shunichi Kouno, and Masao Takemura, and Masakiyo Yatomi, and Haruka Aoki-Saito, and Yasuhiko Koga, and Kenichiro Hara, and Shinsuke Motegi, and Mayuko Tsukida, and Fumie Ota, and Yoshito Tsukada, and Mitsuru Motegi, and Masao Nakasatomi, and Toru Sakairi, and Hidekazu Ikeuchi, and Yoriaki Kaneko, and Keiju Hiromura, and Toshitaka Maeno
September 2011, Journal of the American Academy of Dermatology,
Koichi Yamaguchi, and Aya Yamaguchi, and Masashi Ito, and Ikuo Wakamatsu, and Miki Itai, and Sohei Muto, and Shogo Uno, and Masaki Aikawa, and Shunichi Kouno, and Masao Takemura, and Masakiyo Yatomi, and Haruka Aoki-Saito, and Yasuhiko Koga, and Kenichiro Hara, and Shinsuke Motegi, and Mayuko Tsukida, and Fumie Ota, and Yoshito Tsukada, and Mitsuru Motegi, and Masao Nakasatomi, and Toru Sakairi, and Hidekazu Ikeuchi, and Yoriaki Kaneko, and Keiju Hiromura, and Toshitaka Maeno
January 2021, Clinical and experimental rheumatology,
Koichi Yamaguchi, and Aya Yamaguchi, and Masashi Ito, and Ikuo Wakamatsu, and Miki Itai, and Sohei Muto, and Shogo Uno, and Masaki Aikawa, and Shunichi Kouno, and Masao Takemura, and Masakiyo Yatomi, and Haruka Aoki-Saito, and Yasuhiko Koga, and Kenichiro Hara, and Shinsuke Motegi, and Mayuko Tsukida, and Fumie Ota, and Yoshito Tsukada, and Mitsuru Motegi, and Masao Nakasatomi, and Toru Sakairi, and Hidekazu Ikeuchi, and Yoriaki Kaneko, and Keiju Hiromura, and Toshitaka Maeno
February 2006, Clinical rheumatology,
Copied contents to your clipboard!